Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines

Author： Neelakantan Pratap   Apperley Jane F  

Publisher： Future Medicine

ISSN： 2044-9038

Source： Clinical Practice, Vol.10, Iss.3, 2013-05, pp. : 283-291

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia

By  

Case Reports in Oncology, Vol. 8, Iss. 1, 2015-03 ,pp. : 122-127

Karger

Access to resources Recommend Favorite

Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

By Yood Marianne Ulcickas   Oliveria Susan A.   Cziraky Mark   Hirji Ishan   Hamdan Muhammad   Davis Catherine  

Current Medical Research and Opinion, Vol. 28, Iss. 2, 2012-02 ,pp. : 213-219

Informa Healthcare

Access to resources Recommend Favorite

Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : E100-E101

John Wiley & Sons Inc

Access to resources Recommend Favorite

More about Imatinib and Nilotinib Combination Therapy in Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-09 ,pp. : 18-19

Karger

Access to resources Recommend Favorite

Dasatinib in the Treatment of Chronic Myeloid Leukemia

By  

Current Signal Transduction Therapy, Vol. 6, Iss. 1, 2011-01 ,pp. : 99-105

Bentham Science Publishers

Access to resources Recommend Favorite